| Date | Name | Symbol | Type | Security | Shares | Price | Value | Ownership | Reported |
| 06/29/2023 | Kiniksa Pharmaceuticals, Ltd. | KNSA | Exercise | Restricted Share Units | 5k | $0.00 | $0 | | 06/29/2023 |
| 06/06/2023 | Kiniksa Pharmaceuticals, Ltd. | KNSA | Grant | Share Option | 26.2k | $15.19 | $398.5k | | 06/06/2023 |
| 06/06/2023 | Kiniksa Pharmaceuticals, Ltd. | KNSA | Grant | Restricted Share Units | 4.4k | $0.00 | $0 | | 06/06/2023 |
| 05/31/2023 | Kura Oncology, Inc. | KURA | Grant | Option to purchase common stock | 26k | $13.32 | $346.3k | | 05/31/2023 |
| 06/29/2022 | Kiniksa Pharmaceuticals, Ltd. | KNSA | Grant | Share Option | 30k | $9.88 | $296.4k | | 06/29/2022 |
| 06/29/2022 | Kiniksa Pharmaceuticals, Ltd. | KNSA | Grant | Restricted Share Units | 5k | $0.00 | $0 | | 06/29/2022 |
| 06/22/2022 | BeiGene, Ltd. | BGNE | Grant | | 16.7k | $0.00 | $0 | | 06/22/2022 |
| 06/22/2022 | BeiGene, Ltd. | BGNE | Grant | Share Option (Right to Buy) | 34.6k | $0.00 | $0 | | 06/22/2022 |
| 06/21/2022 | Kura Oncology, Inc. | KURA | Grant | Option to purchase common stock | 23k | $14.84 | $341.3k | | 06/21/2022 |
| 06/29/2021 | Kiniksa Pharmaceuticals, Ltd. | KNSA | Grant | Share Option | 33.2k | $14.33 | $476.3k | | 06/29/2021 |
| 06/22/2021 | Kura Oncology, Inc. | KURA | Grant | Option to purchase common stock | 23k | $21.54 | $495.4k | | 06/22/2021 |
| 06/16/2021 | BeiGene, Ltd. | BGNE | Grant | | 7.8k | $0.00 | $0 | | 06/16/2021 |
| 06/16/2021 | BeiGene, Ltd. | BGNE | Grant | Share Option (Right to Buy) | 17.5k | $0.00 | $0 | | 06/16/2021 |
| 06/30/2020 | Kiniksa Pharmaceuticals, Ltd. | KNSA | Grant | Share Option | 18.8k | $25.48 | $478k | | 06/30/2020 |
| 06/24/2020 | Kura Oncology, Inc. | KURA | Grant | Option to purchase common stock | 23k | $17.97 | $413.3k | | 06/24/2020 |
| 06/17/2020 | BeiGene, Ltd. | BGNE | Grant | Share Option (Right to Buy) | 45.4k | $0.00 | $0 | | 06/17/2020 |
| 06/25/2019 | Kura Oncology, Inc. | KURA | Grant | Option to purchase common stock | 13k | $19.55 | $254.2k | | 06/25/2019 |
| 06/05/2019 | BeiGene, Ltd. | BGNE | Grant | Share Option (Right to Buy) | 64.6k | $0.00 | $0 | | 06/05/2019 |
| 05/29/2019 | Kiniksa Pharmaceuticals, Ltd. | KNSA | Grant | Share Option | 18.8k | $15.47 | $290.2k | | 05/29/2019 |
| 06/07/2018 | Kura Oncology, Inc. | KURA | Grant | Option to purchase common stock | 13k | $16.35 | $212.6k | | 06/07/2018 |
| 06/06/2018 | BeiGene, Ltd. | BGNE | Grant | | 9.3k | $0.00 | $0 | | 06/06/2018 |
| 06/06/2018 | BeiGene, Ltd. | BGNE | Grant | Share Option (Right to Buy) | 17.4k | $0.00 | $0 | | 06/06/2018 |
| 05/29/2018 | Kiniksa Pharmaceuticals, Ltd. | KNSA | Conversion | Class A Common Shares | 72k | $0.00 | $0 | See footnote | 05/29/2018 |
| 05/29/2018 | Kiniksa Pharmaceuticals, Ltd. | KNSA | Conversion | Series B Preferred Shares | 72k | $0.00 | $0 | See footnote | 05/29/2018 |
| 06/13/2017 | Tempest Therapeutics, Inc. | OVAS | Grant | Common Stock | 7.9k | $0.00 | $0 | | 06/13/2017 |
| 06/09/2017 | Kura Oncology, Inc. | KURA | Grant | Option to purchase common stock | 10k | $8.60 | $86k | | 06/09/2017 |
| 06/02/2017 | BeiGene, Ltd. | BGNE | Grant | Share Option (Right to Buy) | 170k | $0.00 | $0 | | 06/02/2017 |
| 03/31/2017 | Tempest Therapeutics, Inc. | OVAS | Grant | Common Stock | 7.1k | $0.00 | $0 | | 03/31/2017 |
| 12/30/2016 | Tempest Therapeutics, Inc. | OVAS | Grant | Common Stock | 8.7k | $1.53 | $13.2k | | 12/30/2016 |
| 11/23/2016 | BeiGene, Ltd. | BGNE | Purchase | | 30k | $32.00 | $960k | | 11/23/2016 |
| 09/30/2016 | Tempest Therapeutics, Inc. | OVAS | Grant | Common Stock | 1.8k | $0.00 | $0 | | 09/30/2016 |
| 06/30/2016 | Tempest Therapeutics, Inc. | OVAS | Grant | Common Stock | 2.5k | $0.00 | $0 | | 06/30/2016 |
| 06/02/2016 | Tempest Therapeutics, Inc. | OVAS | Grant | Stock Option (right to buy) | 12k | $7.38 | $88.6k | | 06/02/2016 |
| 06/01/2016 | Tempest Therapeutics, Inc. | OVAS | Grant | Common Stock | 50k | $7.00 | $350k | | 06/01/2016 |
| 03/31/2016 | Tempest Therapeutics, Inc. | OVAS | Grant | Common Stock | 1.4k | $0.00 | $0 | | 03/31/2016 |
|